Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Little Rock, Arkansas 72205


Purpose:

RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with unresectable locally advanced or metastatic colorectal cancer.


Study summary:

OBJECTIVES: - Determine the confirmed response (complete and partial) in patients with previously treated unresectable locally advanced or metastatic colorectal cancer treated with FR901228 (depsipeptide). - Determine the time to treatment failure and overall survival of patients treated with this drug. - Determine the qualitative and quantitative toxic effects of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks until disease progression and then every 3 months until 1 year after study entry and then every 6 months until 3 years after study entry. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 4-10 months.


Criteria:

DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed colorectal cancer meeting 1 of the following criteria: - Locally advanced unresectable disease - Distant metastatic disease - Measurable disease - Previously treated with at least 1, but no more than 2, prior chemotherapy regimens for unresectable locally advanced or metastatic disease - May have included irinotecan or oxaliplatin - No more than 1 prior chemotherapy regimen (not oxaliplatin-based) for advanced or metastatic disease if previously treated with oxaliplatin-based adjuvant chemotherapy - No more than 1 prior chemotherapy regimen (not irinotecan-based) for advanced or metastatic disease if previously treated with irinotecan-based adjuvant chemotherapy - No known brain metastases PATIENT CHARACTERISTICS: Age - Over 18 Performance status - Zubrod 0-1 Life expectancy - Not specified Hematopoietic - WBC ≥ 3,000/mm^3 - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 Hepatic - Bilirubin ≤ upper limit of normal (ULN) - SGOT and SGPT ≤ 2.5 times ULN Renal - Creatinine ≤ ULN Cardiovascular - No New York Heart Association class III or IV congestive heart failure - No myocardial infarction within the past year - No uncontrolled dysrhythmias - No poorly controlled angina - No prior serious ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row) - No left ventricular hypertrophy - QTc < 500 msec - No other significant cardiac disease Other - Not pregnant or nursing - Fertile patients must use effective contraception - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No prior allergic reaction attributed to compounds of similar chemical or biological composition to FR901228 PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent anticancer immunotherapy Chemotherapy - See Disease Characteristics - At least 28 days since prior chemotherapy and recovered - No prior FR901228 (depsipeptide) - No other concurrent anticancer chemotherapy Endocrine therapy - No concurrent anticancer hormonal therapy Radiotherapy - At least 28 days since prior radiotherapy and recovered - No concurrent anticancer radiotherapy Surgery - At least 28 days since prior surgery and recovered Other - No concurrent combination antiretroviral therapy for HIV-positive patients - No concurrent agent that causes QTc prolongation - No concurrent hydrochlorothiazide - No other concurrent investigational agents - No other concurrent drugs that have histone deacetylase inhibitor activity (e.g., valproic acid) - No other concurrent anticancer therapy


Study is Available At:


Original ID:

CDR0000350199


NCT ID:

NCT00077337


Secondary ID:

SWOG-S0336


Study Acronym:


Brief Title:

FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer


Official Title:

Phase II Trial of Depsipeptide (NSC-630176) in Colorectal Cancer Patients Who Have Received Either One or Two Prior Chemotherapy Regimens for Metastatic or Locally Advanced, Unresectable Disease


Overall Status:

Completed


Study Phase:

Phase 2


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Cancer Institute (NCI)


Oversight Authority:

United States: Federal Government


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Masking: Open Label, Primary Purpose: Treatment


Number of Arms:

0


Number of Groups:

0


Total Enrollment:

0


Enrollment Type:


Overall Contact Information

Official Name:Robert P. Whitehead, MD
University of Texas

Study Dates

Start Date:April 2004
Completion Date:April 2006
Completion Type:Actual
Verification Date:November 2005
Last Changed Date:June 21, 2013
First Received Date:February 10, 2004

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:romidepsin

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Southwest Oncology Group
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Whitehead RP, McCoy S, Wollner IS, et al.: Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study. [Abstract] American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, California. A-255, 2006.
Reference Type:Results Reference
Citation:Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL, Blanke CD. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2008 Oct 22; [Epub ahead of print]
PMID:18941712

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.